{"id":"W4221044986","doi":"10.1038/s41591-022-01731-4","title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemoimmunotherapy; Oncology; Cytokine release syndrome; Phases of clinical research; Lymphoma; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405564,0.0008408501,0.001059342,0.0003901167,0.0001979461,0.0007969118,0.0005400062,0.0009696023,0.00390499],"category_scores_gemma":[0.0006648717,0.0002649088,0.0006375393,0.00027621,0.0004753665,0.0005392779,0.000308098,0.001831482,0.0007568045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000504662,"about_ca_system_score_gemma":0.0006819405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004776769,"about_ca_topic_score_gemma":0.001376638,"domain_scores_codex":[0.9997396,0.0001492167,0.000007326756,0.00002913261,0.00003068378,0.00004412595],"domain_scores_gemma":[0.999719,0.00005431563,0.00005626879,0.00001909245,0.0000142824,0.0001370644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.677249,0.03038931,0.005778193,0.002071471,0.001405144,0.0003520185,0.0002059685,0.00329872,0.02457438,0.0008300989,0.01364173,0.2402039],"study_design_scores_gemma":[0.772118,0.2007395,0.009929328,0.0001523536,0.0006071234,0.0004783198,0.00005635837,0.002763385,0.003760541,0.0004703526,0.008894653,0.00003009962],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776536,0.01244951,0.0007143207,0.00107686,0.0002786983,0.001713491,0.001289607,0.0002662817,0.004557698],"genre_scores_gemma":[0.9786618,0.005641044,0.002007435,0.001448064,0.0003239783,0.002644604,0.002975931,0.00004952214,0.006247613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00390499,"threshold_uncertainty_score":0.01306355,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02147039958810337,"score_gpt":0.3415673981146957,"score_spread":0.3200969985265923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}